Showing 4391-4400 of 7364 results for "".
- Almirall, MC2 Therapeutics Strike Deal to Distribute Wynzora in Europehttps://practicaldermatology.com/news/almirall-mc2-therapeutics-strike-deal-to-distribute-wynzora-in-europe/2460692/
- Breaking Business News: Evolus' Jeuveau Can Stay on U.S. Market For Nowhttps://practicaldermatology.com/news/breaking-business-news-evolus-jeuveau-can-stay-on-us-market-for-now/2460690/Evolus Inc. can remain for sale in the U.S. temporarily while an appeals court re-considers an import ban won by AbbVie Inc.’s Allergan that was slated to go into effect on Feb. 16, 2021, according to
- Potential Psoriasis Breakthrough: Bimekizumab Performs Well in Moderate-to-Severe Plaque Psoriasishttps://practicaldermatology.com/news/potential-psoriasis-breakthrough-bimekizumab-performs-well-in-moderate-to-severe-plaque-psoriasis/2460684/Two new Phase 3 studies show that bimekizumab-treated psoriasis patients achieved superior levels of skin clearance compared to those who received placebo or ustekinumab. The safety profile of bimekizumab was consistent with earlier clinical studies with no new safety signals identified
- Injecting Nanoparticles Into Skin Cancers May Be An Alternative to Surgeryhttps://practicaldermatology.com/news/is-injecting-nanoparticles-into-skin-cancers-an-alternative-to-surgery/2460677/Yale researchers are developing a skin cancer treatment that involves injecting nanoparticles into the tumor, killing cancer cells with a two-pronged approach, as a potential alternative to surgery. The results are published in the Proceedings of the National Academy of Science
- Arcutis Moves Another Candidate Into Phase 3 Trialshttps://practicaldermatology.com/news/arcutis-moves-another-candidate-into-phase-3-trials/2460664/Roughly a week after announcing plans to initiate Phase 3 clinical trials for topical roflumilast cream (ARQ-151) in the treatment of atopic dermatitis (AD),
- MyHealthTeams' "Gaining Control with Psoriasis" Challenge Empowers Psoriasis Patients to Change Things Uphttps://practicaldermatology.com/news/myhealthteams-gaining-control-with-psoriasis-challenge-empowers-psoriasis-patients-to-change-things-up/2460663/
- Gene Sequencing May Quantify Risk of Skin Cancer Long Before Damage is Visiblehttps://practicaldermatology.com/news/gene-sequencing-may-quantify-risk-of-skin-cancer-long-before-damage-is-visible/2460644/New research sheds light on the carcinogenic effect of exposure to ultraviolet (UV) radiation, laying the groundwork for improvements in skin cancer risk stratification and prevention. In a study published&nbs
- Evelo's AD Candidate Meets Phase 1b Endpointshttps://practicaldermatology.com/news/evelos-ad-candidate-meets-phase-1b-endpoints/2460631/Evelo Biosciences, Inc.’s investigational atopic dermatitis treatment EDP1815 was well tolerated with no serious adverse events in a phase 1b clinical trial. According to the company, the oral drug candidate studied in 23 evaluable subjects with
- UCB, Stanford Medicine Partner to Seek New Ways to Treat HS, Other Diseaseshttps://practicaldermatology.com/news/ucb-stanford-medical-partner-to-seek-new-ways-to-treat-hs-other-diseases/2460613/UCB and
- More Positive Phase 3 Data for Pfizer's Abrocitinib in ADhttps://practicaldermatology.com/news/more-positive-phase-3-data-for-pfizers-abrocitinib-in-ad/2460607/Positive top-line results from the phase 3 JADE REGIMEN study offer additional data in support of Pfizer's investigational oral once-daily Janus kinase 1 (JAK1) inhibitor for atopic dermatitis (AD). The 52-week study looked at patients 12 and older wi